Challenges in the Pharmacokinetics of Therapeutic Proteins

Limothai, Wararat

doi:10.21007/etd.cghs.2015.0184

Cited by 1 publication

(1 citation statement)

References 109 publications

(271 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For FcRn, for example, data have been limited to rodent studies. While messenger RNA (mRNA) expression of the α-chain of FcRn in rats suggested an age-associated increase ( Tian et al, 2014 ), more recent results on age-associated expression at the protein level in mice suggest no relevant differences in expression from newborn through juvenile animals to adults in skin and spleen tissues ( Limothai, 2015 ), which may be interpreted as more definitive due to the often limited mRNA-to-functional protein correlation for many endogenous proteins including FcRn ( Li and Balthasar, 2018 ; Temrikar et al, 2020 ). There are currently no human data yet available on the ontogeny of FcRn, especially in very young pediatric patients.…”

Section: Differences In Therapeutic Protein Disposition Between Child...mentioning

confidence: 99%

Knowledge Gaps in the Pharmacokinetics of Therapeutic Proteins in Pediatric Patients

Meibohm

2022

Front. Pharmacol.

View full text Add to dashboard Cite

Therapeutic proteins such as monoclonal antibodies and their derivatives, fusions proteins, hormone analogs and enzymes for replacement therapy are an ever-growing mainstay in our pharmacopoeia. While a growing number of these medications are developed for and used in younger and younger pediatric patients, knowledge gaps in the basic understanding of the molecular and physiologic processes governing the disposition of these compounds in the human body and their modulation by age and childhood development are a hindrance to the effective and timely development and clinical use of these compounds, especially in very young pediatric patient populations. This is particularly the case for the widespread lack of information on the ontogeny and age-associated expression and function of receptor systems that are involved in the molecular processes driving the pharmacokinetics of these compounds. This article briefly highlights three receptor systems as examples, the neonatal Fc receptor, the asialoglycoprotein receptor, and the mannose receptor. It furthermore provides suggestions on how these gaps should be addressed and prioritized to provide the field of pediatric clinical pharmacology the urgently needed tools for a more effective development and clinical utilization of this important class of drugs with rapidly evolving importance as cornerstone in pediatric pharmacotherapy.

show abstract

Section: Differences In Therapeutic Protein Disposition Between Child...mentioning

confidence: 99%

Knowledge Gaps in the Pharmacokinetics of Therapeutic Proteins in Pediatric Patients

Meibohm

2022

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

Challenges in the Pharmacokinetics of Therapeutic Proteins

Cited by 1 publication

References 109 publications

Knowledge Gaps in the Pharmacokinetics of Therapeutic Proteins in Pediatric Patients

Knowledge Gaps in the Pharmacokinetics of Therapeutic Proteins in Pediatric Patients

Contact Info

Product

Resources

About